- Shares of Intrexon (XON +1.4%) look to close modestly higher after the company's $26M deal for California-based Medistem (MEDS +47.7%) which develops Endometrial Regenerative Cells.
- XON says the cells "have the potential to provide treatments for conditions such as cancer, wound healing, and cardiovascular disease," when combined with integrated synthetic biology platforms.
- More specifically, XON plans to "develop two powerful classes of clinical products": Engineered stem cells for "therapeutic delivery of secreted proteins" and for "producing exosomes."
- MEDS shareholders are getting $0.27 in cash and "$1.08 worth of XON common stock." (PR)
From other sites
at 4-traders.com (Mar 25, 2015)
at Zacks.com (Mar 24, 2015)
at Zacks.com (Mar 11, 2015)
at Zacks.com (Mar 6, 2015)
at Nasdaq.com (Jan 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs